Impact Biomedical (IBO) Capital Expenditures (2023)

Impact Biomedical's (IBO) quarterly Capital Expenditures came in at $1000.0 in Q3 2023, down 91.67% on a QoQ basis from $12000.0 in Q2 2023.

Impact Biomedical (IBO) Capital Expenditures (2023) Analysis & Trends

Impact Biomedical (IBO) has 1 years of Capital Expenditures data on file, last reported at $1000.0 in Q3 2023.

Quarterly Capital Expenditures changed N/A year-over-year to $1000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $18000.0 (changed N/A YoY) and the FY2023 annual result came in at $18000.0, down 93.48% from the prior year.
Capital Expenditures slipped to $1000.0 in Q3 2023, from $12000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $12000.0 in Q2 2023 to a low of $1000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	34.68 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.26 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	251.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-73.57 Mn
10	Impact Biomedical	49.45 Mn	49.44 Mn	2,000.00	-

Download Data